Business
Pond Technologies Holdings Inc. Appoints John M. Farah Jr, Ph.D to Board of Directors Strategic Appointment to Assist in Pond Biotech Expansion
MARKHAM, ON / ACCESSWIRE / July 14, 2021 / Pond Technologies Holdings Inc. (the " Corporatio...
About this update from Pond Technologies Holdings Inc.
[{"type":"text","content":"Pond Technologies Holdings Inc. Appoints John M. Farah Jr, Ph.D to Board of Directors Strategic Appointment to Assist in Pond Biotech ExpansionMARKHAM, ON / ACCESSWIRE / July 14, 2021 / Pond Technologies Holdings Inc. (the \"Corporation\" or \"Pond\") (TSX.V:POND), (OTCQB:PNDHF) an ESG company addressing global sustainability challenges of climate change and nutrition, is pleased to announce John M. Farah Jr, Ph.D has been appointed to the Board of Directors.John M. Farah Jr, Ph.D has over 30 years of experience in health care and the biopharmaceutical industry. He is currently a senior clinical consultant with Veradigm, an Allscripts business, leveraging real-world data and real-world evidence for insights into challenges and opportunities in care of patients with chronic health conditions. He is also a member of the industry advisory board for the Coulter-Drexel Translational Research Partnership Program (Drexel University). John has advised clients in drug and biologic development and corporate partnering as Managing Director of his own consultancy and in market access and market research with agencies like rjSynergy. John began advising small to mid-sized firms after 19 years at Cephalon (now Teva) where he became Vice President of international pharmaceutical operations. John has broad expertise in R&D, business development, and ex-US commercialization with specialization in Asia Pacific and Latin American markets. He had focused on products for neurosciences & pain, hematology & oncology, and infectious & inflammatory disorders for Cephalon.In addition, John co-led successful intellectual property litigation efforts in Europe and Latin America and was Treasurer and director of Cephalon's political action committee. John has over 10 years of experience as an independent director on the boards of public US companies including service on audit, compensation, and governance committees. John is author and inventor on over 40 publications, whitepapers, and patents. He started his industry career as a research investigator in neurosciences and immune-inflammatory programs at G.D. Searle & Co. (now Pfizer).John earned his doctorate in physiology from the Uniformed Services University and conducting post-doctoral studies in the Neurological Disorders and Stroke division of the National Institutes of Health. He h...